Search results
-
DLL3 goes trispecific
… Harpoon) Ph1/2 data in 2nd-line solid tumours at ESMO 2023: ORR 35% across tumour types; ifinatamab-dxd combo …
- 06/20/2025 - 20:42 -
NextCure joins Merck in an ovarian target
… Ph3 Rejoice-Ovarian01 completes Dec 2027; ph1 data at ESMO 2023: cORR 46% (23/50) in ovarian cancer* CUSP06 …
- 06/19/2025 - 11:19 -
Lepu starts another pivotal conjugate trial
… similar setting will feature in a late-breaking session. At ESMO 2023 the same phase 2 produced ORRs of 39% and 55% with …
- 05/22/2025 - 13:39 -
Novartis gets a PSMAfore green flag at last
… or a different androgen-receptor-targeting therapy. At ESMO 2023 it became apparent that, although the study had … Final analysis 2nd interim analysis (ESMO 2023) Crossover 60% 84% OS HR … 0.38-0.91 0.48-1.33 Source: company releases & ESMO 2023. This was clearly enough for the FDA; the …
- 04/01/2025 - 16:46 -
ELCC 2025 – BioNTech impresses in small-cell lung
… 42% – lower than the 73% reported from the same study at ESMO 2023. Still, the result is in line with the 40% ORR …
- 04/01/2025 - 16:09 -
AACR 2025 preview – distressed biotechs seek redemption
… Ph1 low-dose irinotecan combo Had monoRx data at ESMO 2023 D3S-001 KRAS G12C inhibitor D3 Bio …
- 03/28/2025 - 08:55 -
Imfinzi puts its flag on the Matterhorn
… already read out positively for pCR, with data presented at ESMO 2023, but the trial remained blinded for EFS, and it's … PD-L1 at a level of at least 1%. It will be noted that ESMO 2023 showed Matterhorn's pCR benefit to be strongest in …
- 03/11/2025 - 15:11 -
Bristol exits KRAS G12D
… Hengrui) Inhibitor Lacklustre ph1 data at ESMO 2023 GFH375 Verastem/GenFleet Inhibitor …
- 03/06/2025 - 13:30 -
ASCO-GU – Pfizer looks for bigger bladder cancer invasion
… urothelial cancer + Keytruda, vs chemo Data at ESMO 2023: 53% reduction in risk of death; FDA approved Dec …
- 02/12/2025 - 15:51 -
Two more reasons for GSK to be wary of Tim-3
… as sabestomig had posted mediocre efficacy data at ESMO 2023 . Its discontinuation means that GSK's cobolimab …
- 02/06/2025 - 15:35
